Jia Ying, Zhang Yuanyuan, Tai Xin, Zhao Tengyu, Zhang Hanwen, Zhou Haichun
The Second Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, China.
The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Front Pharmacol. 2025 Sep 8;16:1667694. doi: 10.3389/fphar.2025.1667694. eCollection 2025.
Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with α-synuclein deposition and dopaminergic neuron degeneration. Recent studies have revealed a close correlation between gut microbiota dysbiosis and the pathogenesis and progression of PD. Gut microbiota may influence the disease through multiple pathways, including promoting α-synuclein pathology, disrupting the gut-brain barrier, and triggering inflammation and neuronal damage. Currently, drug treatments for PD primarily focus on compensating for dopaminergic neurotransmission deficits, delaying neuronal degeneration, and clearing abnormal protein aggregates. However, these drugs can only slow disease progression and are associated with significant adverse effects. In contrast, natural products exhibit distinct advantages in modulating PD pathological features by targeting the "gut microbiota-metabolite axis," owing to their multi-target synergistic regulation and favorable safety profiles, making them an ideal strategy for PD intervention. Based on this, we provide a comprehensive review of natural products that regulate the gut microbiota, analyze their specific mechanisms, and offer novel insights into this approach and provide a theoretical foundation for developing safe and effective PD therapeutics.
帕金森病(PD)是一种与α-突触核蛋白沉积和多巴胺能神经元变性相关的进行性神经退行性疾病。最近的研究表明,肠道微生物群失调与PD的发病机制和进展密切相关。肠道微生物群可能通过多种途径影响该疾病,包括促进α-突触核蛋白病理变化、破坏肠-脑屏障以及引发炎症和神经元损伤。目前,PD的药物治疗主要集中在补偿多巴胺能神经传递缺陷、延缓神经元变性以及清除异常蛋白质聚集体。然而,这些药物只能减缓疾病进展,并且伴有显著的不良反应。相比之下,天然产物由于其多靶点协同调节作用和良好的安全性,在通过靶向“肠道微生物群-代谢物轴”调节PD病理特征方面具有明显优势,使其成为PD干预的理想策略。基于此,我们对调节肠道微生物群的天然产物进行了全面综述,分析了它们的具体机制,并为该方法提供了新的见解,为开发安全有效的PD治疗药物奠定了理论基础。